COAPT trial is a randomized controlled trial that had two groups; one group was assigned to GDMT while the other group had mitra clip in place in addition to the GDMT.
In conclusion, COAPT trial showed that in patients with moderate-to-severe or severe secondary mitral regurgitation with heart failure who remained symptomatic despite the use of maximal doses of GDMT, transcatheter mitral valve repair (MitraClip) resulted in a lower rate of hospitalization for heart failure, lower mortality, and better quality of life and functional capacity within 24 months of follow-up than medical therapy alone.
Even though all patients were in stable condition with fixed GDMT
before study enrollment, some changes might happen during the course of study
Jude, these data show a strong improvement for patients managed by optimal GDMT and the CardioMEMS HF System in both mortality and hospitalizations over currently defined best practices.
The analysis looked at patients with HF and reduced ejection fraction (HFrEF) (when the heart muscle does not contract effectively and less oxygen-rich blood is pumped out to the body) over an average of 17months who were on optimal GDMT and compared those managed by PA pressure monitoring with the CardioMEMS HF System to those managed by SOC.
Serial measurements can be used to titrate GDMT
to optimal doses.
Provided that patient renal function is "reasonably intact," the drugs are a valuable addition to GDMT.
* Using in-hospital systems that identify heart failure patients appropriate for GDMT and prompt physicians to advance this care and assess response.